Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16708694 | 0.81 | MAP3K5 (0.34) | MAP3K5ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL26606393 | 0.80 | SCN9A (0.38) | MAP3K5SCN9AHTR1DCYP1A2CYP2C9 | |
| SCHEMBL12602665 | 0.77 | MEN1 (0.35) | MAP3K5SCN9AHTR1DCYP1A2CYP2C9 | |
| SCHEMBL22315767 | 0.74 | SCN9A (0.35) | SCN9A | |
| SCHEMBL16728930 | 0.74 | TP53 (0.38) | MAP3K5SCN9ATP53 | |
| SCHEMBL18538056 | 0.74 | TP53 (0.38) | SCN9AHTR1DALDH1A1TP53 | |
| SCHEMBL16727214 | 0.73 | TP53 (0.42) | MAP3K5ALDH1A1POLBTP53 | |
| SCHEMBL16727209 | 0.71 | MAP3K5 (0.32) | MAP3K5TP53 | |
| SCHEMBL18508820 | 0.71 | TP53 (0.50) | MAP3K5ALDH1A1TP53 | |
| SCHEMBL26144296 | 0.71 | HTR1D (0.47) | MAP3K5SCN9AHTR1DALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MAP3K5 2202/4885SCN9A 3573/4885HTR1D 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.